4.5 Article

Older Adult Oncology, Version 1.2021 Featured Updates to the NCCN Guidelines

期刊

出版社

HARBORSIDE PRESS
DOI: 10.6004/jnccn.2021.0043

关键词

-

类别

资金

  1. Agios Pharmaceuticals
  2. AstraZeneca
  3. Clovis Oncology, Inc.
  4. Daiichi Sankyo
  5. Eisai
  6. Epizyme Inc.
  7. Novartis
  8. Pharmacyclics LLC
  9. AbbVie Company
  10. Janssen Biotech, Inc.
  11. Bristol-Myers Squibb
  12. Regeneron Pharmaceuticals, Inc.
  13. Sanofi Genzyme
  14. Mylan Inc.
  15. Karyopharm Therapeutics
  16. AbbVie

向作者/读者索取更多资源

The NCCN Guidelines for Older Adult Oncology address specific issues related to cancer management in older adults, with a focus on comprehensive geriatric assessment (CGA) as a multidisciplinary evaluation method to assess health status and various domains relevant to cancer treatment choices. Recent updates to the guidelines provide a specific practical framework for using CGA in evaluating older adults with cancer.
The NCCN Guidelines for Older Adult Oncology address specific issues related to the management of cancer in older adults, including screening and comprehensive geriatric assessment (CGA), assessing the risks and benefits of treatment, preventing or decreasing complications from therapy, and managing patients deemed to be at high risk for treatment-related toxicity. CGA is a multidisciplinary, in-depth evaluation that assesses the objective health of the older adult while evaluating multiple domains, which may affect cancer prognosis and treatment choices. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines providing specific practical framework for the use of CGA when evaluating older adults with cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据